linjc16/ctgov huggingface dataset:
Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists

Study Overview
=================
Brief Summary
-----------------
This study aims to examine the opinions and needs of pharmacists and pharmaceutical technical assistants (FTA) concerning their role as gatekeepers in suicide prevention. The primary objective is to map the experiences and needs of (public) pharmacists and FTA with regard to suicide prevention. The secondary objective is to be able to develop more targeted tools, interventions or trainings based on the results of the needs assessment in order to facilitate the role of (public) pharmacists and FTA as gatekeepers in suicide prevention.

Official Title
-----------------
Role of Pharmacists in Suicide Prevention: Needs Assessment Among Pharmacists

Conditions
-----------------
Pharmacist-Patient Relations, Suicide, Suicide, Attempted, Suicidal Ideation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Working as a (public) pharmacist or pharmaceutical technical assistant (FTA) 18 years or older Access to a computer, tablet or mobile phone with internet access Dutch-speaking Exclusion Criteria: Hospital pharmacists or industrial pharmacists are not included in this study and thus constitute an exclusion criterion.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pharmacists and pharmaceutical technical assistants (FTA)<br>Dutch-speaking Belgian public pharmacists or pharmaceutical technical assistants (FTA) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Needs | Questionnaire based on a study by Gillette et al. (2020), scientific literature and previous needs surveys conducted by VLESP. In collaboration with the Flemish Pharmacists Network. Socio-demographics; Perceptions, attitudes and barriers: 55 statements (completely disagree, disagree, neutral, agree, completely agree); Contact with suicidal person (never/rarely, few times a year, monthly, weekly, daily), experience (very un-, rather un-, neutral, experienced, very experienced), possible actions as gatekeeper, referral, known organizations/helplines, previous education (yes or no), knowledge (yes/no)/ satisfaction (not at all, rather not, neutral, rather, very) existing education; Preparedness/need training (not at all, rather not, neutral, rather, very), preferred format of training, needed information; Suicidal thoughts/attempts (yes/no), hopelessness: 4 items (true/false) | Baseline. Completing the questionnaire will take approximately 15-20 minutes. |
Medicinal Nicotine for Preventing Cue Induced Craving

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if changing the timeframe (relative to cue presentation) at which the nicotine lozenge is given can attenuate the increase in symptoms of tobacco craving and withdrawal that occur when smokers are presented with smoking cues. In this cross-over study, all subjects attend three laboratory sessions at which either nicotine lozenge or placebo is given prior to presentation of smoking cues or after presentation of smoking cues. The order in which the three conditions will be presented are randomized.

Conditions
-----------------
Tobacco Use Disorder

Intervention / Treatment
-----------------
* Drug: Nicotine lozenge 4 mg
* Drug: Placebo lozenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smoking a minimum number of cigarettes per day General good health Exclusion Criteria: unstable medical or psychiatric conditions history of severe motion sickness (due to virtual reality equipment used to present cues) women who are pregnant or breast feeding The investigators will evaluate if there are other reasons why someone may not participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nicotine lozenge 4 mg prior to cue exposure<br>Nicotine lozenge is used 15 minutes prior to smoking cue exposure | Drug: Nicotine lozenge 4 mg<br> <br> |
| Placebo Comparator: Placebo lozenge prior to cue exposure<br>Placebo lozenge is used 15 minutes prior to smoking cue exposure | Drug: Placebo lozenge<br> <br> |
| Other: Control condition: Lozenge after cue exposure<br>Lozenge is used immediately after smoking cue exposure | Drug: Nicotine lozenge 4 mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Craving Symptom Severity Score Assessed Via Questionnaire | Craving as assessed via the craving question on the Minnesota Nicotine Withdrawal Scale. The score range is from 0 (no craving) to 4 (severe craving). The outcome measure is the change in craving score from before cue exposure to craving score after cue exposure. | approximately 15 minutes | 
| Withdrawal Symptom Severity Score Assessed Via Questionnaire | Withdrawal as assessed via the Minnesota Nicotine Withdrawal Scale. The score range is from 0 to 28 with higher scores indicating more severe withdrawal symptoms. The outcome measure is the change in withdrawal score from before cue exposure to the withdrawal score after cue exposure. | approximately 15 minutes |
Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes

Study Overview
=================
Brief Summary
-----------------
This is an observational prospective study. Role of EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration) is evaluated to diagnose tuberculosis in mediastinal and/or hilar lymph nodes. The investigators analyse the specificity and sensibility of this technique to diagnose tuberculosis in mediastinal and/or hilar lymph nodes. Patients with mediastinal and/or hilar lymph nodes on X-ray or CT thorax where a tuberculosis is the most probable cause and who have no parenchymal lesions suspected for tuberculosis and without other lymph nodes that are more easily accessible or palpable will be included in this study.

Official Title
-----------------
Role of EBUS-TBNA (Endobronchial Ultrasound Transbronchial Needle Aspiration- in Diagnosing Tuberculosis in Mediastinal and/or Hilar Lymph Nodes

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Procedure: EBUS-TBNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with enlarged mediastinal and/or hilar lymph nodes on chest CT highly suspicious of tuberculosis (suggestive clinical history, suggestive echographic findings ...) without pulmonary lesions suspicious for tuberculosis or in whom the first evaluation with sputum examination, classical bronchoscopy, induced sputum didn't result in any diagnosis. patients aged 18 years or older patients need to sign the consent form after reading the information form Exclusion Criteria: synchronic pulmonary lesions suspicious for tuberculosis or already proven tuberculosis by microscopic exam, PCR-technique and/or culture other affected ganglionary sites more easily accessible (cervical, supraclavicular, axillary ... region)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EBUS<br>patients undergoing EBUS | Procedure: EBUS-TBNA<br>* endobronchial ultrasound transbronchial needle aspiration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The ratio of tuberculosis in mediastinal lymph nodes |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mediastinal tuberculosis, endoscopy, EBUS, tuberculous lymphadenopathy, endobronchial ultrasound
Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the knowledge, the attitudes and the practices of parents of asthmatic children.

Detailed Description
-----------------
The aim of this study is to assess the knowledge, the attitudes and the practices of parents of asthmatic children. The study proposes the validation of Q- KAP by means of the recruiting of 390 parents of asthmatic children, recruited in the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy. Q-KAP will be given to one of the parents during their children medical examination. Q-KAP is a multiple answer questionnaire investigating on knowledge, attitudes and practices for what concerns Asthma. At the end of the recruitment time, data will be stored and analyzed in a dataset. The expected result is the identification of a tool able to assess knowledge, attitudes and practices of asthmatic children parents, but also the identification of a tool able to identify two groups of parents (well-experienced and bad-experienced) to assess if there is a link between a low degree of knowledge and a bad control of the disease.

Official Title
-----------------
Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: Q-Kap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthma Exclusion Criteria: No consent by parents

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with asthma<br> | Other: Q-Kap<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge, attitudes and practices of parents of asthmatic children assessment. |  | 1 year |
SelectSecure 3830 Lead Imaging

Study Overview
=================
Brief Summary
-----------------
This study is designed to collect high-quality shoulder and intracardiac bi-plane fluoroscopic images during two standard arm motions on patients implanted with a market released SelectSecure 3830 lead for the purposes of developing a fracture reliability model.

Official Title
-----------------
SelectSecure 3830 Lead Imaging

Conditions
-----------------
Heart Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Bi-plane fluoroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are at least 18 years of age Patient has a pacing, ICD or CRT system incorporating at least one SelectSecure 3830 lead in the right atrium or right ventricle Patients able and willing to attend imaging session Patients able and willing to give informed consent Pacing capture threshold and pacing impedance of the lead are within normal range at the time of enrollment Patient must be able to accomplish arm flexion and adduction past 90 degrees Exclusion Criteria: Subjects who require a legally authorized representative to obtain consent Subjects with exclusion criteria required by local law (e.g. age, breastfeeding) Pregnant women, or women of child bearing potential and who are not on a reliable form of birth control Subjects that were implanted with a pacing, ICD, CRT device and/or cardiac leads less than three months ago

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects undergoing bi-plane fluoroscopy<br> | Diagnostic Test: Bi-plane fluoroscopy<br>* In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect high quality shoulder and intracardiac bi-plane fluoroscopic cine images of the SelectSecure 3830 pacing lead. | Fluoroscopic cine images will be collected in conjunction with a specialized calibration object. When imaging data is processed and analyzed it will characterize the time-varying lead shape changes. | approximately 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acquire accelerometer-based motion data | During fluoroscopy of the two standard arm motions, accelerometer-based motion data will be collected which will allow matching of arm position with lead shape based on the fluoroscopic images. | approximately 30 minutes |
Promoting HPV Vaccine Through Twitter

Study Overview
=================
Brief Summary
-----------------
This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing.

Detailed Description
-----------------
Investigators recruited a convenience sample (n=35) of women ages 18-26 years who resided in public housing in Massachusetts. Investigators assessed the feasibility and acceptability of the campaign. Online assessed changes in HPV knowledge, attitudes, and vaccine intentions before and after the campaign.

Official Title
-----------------
Feasibility of a Twitter Campaign to Promote HPV Vaccine Uptake Among Racially/Ethnically Diverse Young Adult Women Living in Public Housing

Conditions
-----------------
Human Papilloma Virus

Intervention / Treatment
-----------------
* Behavioral: Twitter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English-speaking women Age18-26 years Residents of public housing in two Massachusetts cities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 26 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intervention<br>Twitter messages delivered over 1 month period | Behavioral: Twitter<br>* Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of Humanpapilloma VirusVaccine Knowledge | 13 items that assess knowledge about HPV, the HPV vaccine, and cervical cancer; HPV and cervical cancer risk factors and HPV transmission. Score from 0-100% with higher scores indicating greater knowledge | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vaccination, feasibility, public housing
Association of Plasma Transfusions and Invasive Fungal Infection

Study Overview
=================
Brief Summary
-----------------
Although lacking strong evidences, plasma transfusions are commonly used in critically ill neonates. To date, the relationships between plasma transfusions and nosocomial infection remain controversial and no study has reported the relationships between plasma transfusion and invasive fungal infection (IFI)

Detailed Description
-----------------
Our aim is to explore the association between plasma transfusions and IFI in critically ill neonates

Official Title
-----------------
Association of Plasma Transfusions and Invasive Fungal Infection

Conditions
-----------------
Plasma Administration, Invasive Fungal Infection, Neonatal Infection

Intervention / Treatment
-----------------
* Drug: plasma transfusions
* Drug: non-plasma transfusions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all critically ill neonates admitted in hospital Exclusion Criteria: severe congenital abnormality; died within 24 hours or left neonatal intensive care unit within 24 hours according to their parents' decisions; parents' decision not to participate.

Ages Eligible for Study
-----------------
Minimum Age: 0 Hours
Maximum Age: 24 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| plasma transfusions<br>The critical ill neonates with plasma transfusions | Drug: plasma transfusions<br>* These critical ill neonates with plasma transfusions<br>|
| non-plasma transfusions<br>The critical ill neonates without plasma transfusions | Drug: non-plasma transfusions<br>* These critical ill neonates without plasma transfusions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the rate of invasive fungal infection | the rate of invasive fungal infection in plasma transfusions group | 100 days |
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications

Study Overview
=================
Brief Summary
-----------------
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.

Official Title
-----------------
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications

Conditions
-----------------
Cardiovascular Diseases, Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, who eligible to sign informed consent; Patients with indications to lipid lowing therapy, according to local product document. Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study; Patients with LDL levels: > 3,5 mmol/l Exclusion Criteria: Individual intolerance of atorvastatin, in accordance to local product document.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Main group<br>Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications | Drug: Atorvastatin<br>* Atorvastatin, 10- 80 mg, once daily, 6 month treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit |  | Month 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants Achieving LDL Level ≤ 100 mg/dL at the 1 Month Visit |  | Month 1 | 
| Change From Baseline in Lipid Parameters | Lipid parameters include HDL cholesterol, LDL cholesterol, total cholesterol, and total triglycerides. Change = Month 6 value minus baseline | Month 6 | 
| Percent Change From Baseline in Lipid Parameters | Percent change from baseline calculated as: 100*(change at Month X)/(baseline value). | Month 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Artery Disease, Hyperlipidemia, Atorvastatin